Overview

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
Phase:
Phase 2
Details
Lead Sponsor:
Merrimack Pharmaceuticals
Treatments:
Estrogens
Exemestane
Progesterone